FormaPure RNA
RNA Isolation from FFPE Tissue
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
Agencourt FormaPure RNA provides a simple, automation-friendly process for extracting RNA from formalin-fixed, paraffin-embedded (FFPE) tissue samples. By utilizing the Solid Phase Reversible Immobilization (SPRI) paramagnetic bead-based technology, Agencourt FormaPure RNA does not require vacuum filtration, centrifugation, or organic solvents such as phenol or xylene. Researchers can go from paraffin digestion to total nucleic acid extraction in about four hours (without setup) for 96 samples in a multi-well format utilizing a Biomek liquid handler. Recoveries are consistently higher than competitive techniques.
FormaPure RNA is one of three reagent kits in the FormaPure family, which also includes FormaPure Total for total nucleic acid isolation and FormaPure DNA for DNA isolation. FormaPure reagent kits are a single chemistry system designed and optimized for use in next-generation sequencing (NGS) and other downstream applications including qPCR/ddPCR/PCR.
Brochures
FormaPure Reagent Kits
Manual or Automated RNA, DNA or Total Nucleic Acid Extraction from FFPE
Transcriptomic analysis reveals differential gene expression in African American prostate cancer samples
Prostate cancer is the most frequent cancer in men in the Western world, and its incidence is rapidly increasing. In addition, population-based studies demonstrate that African Americans in the United States have an increased risk of developing prostate cancer. Despite advances in diagnosis and treatment, the molecular mechanisms underlying prostate cancer disparity in African American are not fully understood yet. In this whitepaper from Beckman Coulter Life Sciences, explore a proof of principle study to identify transcriptomic signatures in the African American population using FFPE and fresh frozen samples.
From Genes to Discovery: How Next-Generation Sequencing Reshapes Cancer Research
Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020.1 Prostate cancer ranks as the second-leading cause of cancer-related deaths among American men, surpassed only by lung cancer.2
Join our upcoming webinar featuring Dr. Nallasivam Palanisamy, Henry Ford Health and Zachary Herbert, Dana-Farber Cancer Institute, as they delve into the rapidly escalating role of next-generation sequencing (NGS) in revolutionizing cancer research.
The speakers will examine the pivotal significance of NGS technology in unraveling intricate cancer mysteries. With a focus on prostate cancer, the webinar will highlight transcriptomic signature – a ground-breaking approach to illuminate the genetic nuances underlying cancer disparities, particularly in African American men. The transformative power of transcriptomic analysis will be demonstrated along with insights into the latest advancements and their implication for cancer treatment.
Furthermore, how the automation revolution is reshaping the landscape of cancer research will also be explored. Through pioneering automation techniques, researchers can now manage testing volumes and reduce turnaround times, accelerating the pace of discovery. This innovative approach will be showcased through pilot data displaying the successful application of RNAse1/hybrid capture in a current project.
Dr. Nallasivam Palanisamy is an associate Scientist in the Department of Urology at Henry Ford Health. Palanisamy specializes in prostate cancer, cancer genomics, and molecular cytogenetics/molecular pathology. His research interests are on discovering and characterizing gene fusions in cancer and understanding their role in carcinogenesis from a translational research perspective.
Zachary Herbert is the Director of the Molecular Biology Core Facilities, Lead Scientist at Dana-Farber Cancer Institute, and an Associate Director of the Harvard University Center for AIDS Research Advanced Laboratory Technologies Core. His laboratory primarily focuses on developing and implementing NGS sample preparation, sequencing, and bioinformatics services to advance basic and translational research. He has a BA in Molecular Biology and Biochemistry, a Master’s in Biotechnology, and 20 years of experience running a high-throughput genomics facility.
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global Cancer Observatory: Cancer Today. Lyon: International Agency for Research on Cancer; 2020. Available from URL: https://gco.iarc.fr/today?
American Cancer Society.?Facts & Figures 2023. American Cancer Society. Atlanta, Ga. 2023. Available from URL: https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html??
Key learning objectives
- Explore effective FFPE RNA utilization in NGS for cancer research
- Learn more about the identification of key genes driving aggressive prostate cancer in African Americans, aiding racial disparity workflow understanding
- Discover NGS workflow automation’s role in accelerating tumor biology insights
Who should attend?
- Academia
- Government research
- Contract research organic
- Hospitals
- Clinical
- Pharma
- Biotechnology
- Medical centers
Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
